
Abstract Introduction In anti‐synthetase syndrome (ASyS), long‐term immunosuppression often leads to severe infections, and the use of low‐dose interleukin (IL)‐2 has not been reported in this scenario. Case Description Here, we report a 60‐year‐old woman with ASyS who developed recurrent, refractory infections despite standard immunosuppressive and anti‐infective therapy. Immunophenotyping revealed marked lymphopenia, notably of regulatory T cells (Tregs). After adding low‐dose IL‐2, her fever resolved and symptoms improved. Tregs rose more than threefold, while natural killer (NK) cells and CD8 + T cells also recovered. Inflammatory markers declined, and no adverse events occurred. She remained infection‐free during 7 weeks of follow‐up after stopping IL‐2. Conclusion This case suggests that for patients with ASyS on conventional immunosuppression who develop refractory infections and Treg deficiency, low‐dose IL‐2 may help restore immune balance, in association with expansion of Tregs and recovery of anti‐infectious effector cells such as NK cells and CD8 + T cells.
Abstract Tissue repair and regeneration constitute a complex biological process, meticulously orchestrated by the immune system and stromal microenvironment. In this context, the dynamic crosstalk between regulatory T cells (Tregs) and stromal cells acts as the central regulatory hub. This interactive network precisely coordinates inflammation resolution, tissue regeneration, and immune tolerance through cytokine signaling, direct cell‐cell contact, and microenvironment remodeling. Current research has elucidated its pivotal role at various stages of normal tissue repair; however, its dysregulation also underlies chronic injuries, fibrosis, and autoimmune diseases. In this review, we systematically examine the dynamic regulatory network of the Treg‐stromal cell interaction axis and its role in disease pathogenesis. Furthermore, we propose novel therapeutic strategies targeting this axis to provide theoretical foundations and translational directions for precision immunological interventions in related disorders.
Abstract Background Rheumatoid arthritis is a chronic, systemic disease in which patients can benefit from physical exercise. We conducted a systematic review and meta‐analysis on the effects of physical training on quadriceps muscle strength in individuals with rheumatoid arthritis. Methods A comprehensive search was conducted in PubMed, Embase, Cochrane, Lilacs, Web of Science, Scopus, and gray literature sources (Google Scholar, OpenGray, and ProQuest). The search was performed from inception to November 20, 2025. The inclusion criteria were: patients diagnosed with rheumatoid arthritis; age above 18 years; both sexes; no restrictions on comorbidities; interventions involving physical training. Two authors independently screened studies and assessed the risk of bias using the Cochrane RoB 2 tool. Quadriceps strength was analyzed via pooled estimates and subgroup analyses. Results Nine randomized clinical trials were included in the systematic review. Eight studies (249 participants in the experimental groups and 208 in the control groups) were included in the meta‐analysis, while one study, Seneca et al. (2015), was included only in the narrative synthesis. The overall meta‐analysis showed a significant improvement in quadriceps strength (standardized mean difference [SMD] = 1.56; 95% confidence Interval [CI]: 0.61 to 2.52; p = 0.001; I 2 = 94%). In subgroup analyses, significant effects were observed for both high‐intensity training (SMD = 0.91; 95% CI: 0.33 to 1.49; I 2 = 66%) and moderate/conventional training (SMD = 3.31; 95% CI: 1.13 to 5.50; I 2 = 98%), with a significant subgroup difference ( p = 0.04); however, this difference was not maintained after excluding studies at high risk of bias ( p = 0.49). Fully supervised programs showed a significant effect (SMD = 2.01; 95% CI: 0.78 to 3.25; I 2 = 95%), while the partially supervised/home‐based subgroup was represented by a single study (SMD = 0.56; 95% CI: 0.19 to 0.92). Significant subgroup differences were also observed according to comparator type ( p = 0.004) and strength measurement method ( p = 0.003), but neither remained significant in sensitivity analyses ( p = 0.49 for both). No significant subgroup difference was found according to intervention duration ( p = 0.55). The planned subgroup analysis according to disease stage could not be performed. In the sensitivity analysis excluding studies at high risk of bias, the overall effect remained significant (SMD = 0.94; 95% CI: 0.43 to 1.45; p = 0.0003; I 2 = 56%). No serious adverse events were reported, although safety outcomes were not systematically assessed across studies. Conclusions Physical training leads to significant improvements in quadriceps strength in patients with rheumatoid arthritis. More standardized protocols are needed to optimize exercise prescription for this population.
Abstract The interaction between innate immunity and coagulation is essential in thrombotic diseases, but the molecular links remain unclear. Neutrophils are key players, releasing mediators such as defensins, which are small cationic peptides with antimicrobial functions. Defensins contribute to platelet activation and the formation of neutrophil extracellular traps. This review examines the mechanistic role of defensins in immunothrombosis, focusing on their effects on platelet activation, fibrinolysis, and endothelial function. We also discuss their involvement in autoimmune diseases, such as systemic lupus erythematosus and antiphospholipid syndrome, and evaluate defensins as potential therapeutic targets. α‐ and β‐defensins may serve as biomarkers for thrombotic risk in coronary artery disease, coronavirus disease 2019, and sepsis. Mechanistically, defensins impair clot dissolution, enhance platelet aggregation, and disrupt the von Willebrand factor/ADAMTS13 balance. Colchicine reduces defensin‐mediated thrombosis by inhibiting neutrophil degranulation, suggesting a promising treatment strategy. Targeting defensin offers a potential therapeutic approach for managing thrombotic complications in inflammatory and autoimmune diseases.
Abstract Biologic therapies have greatly improved the outcome of chronic inflammatory conditions such as rheumatoid arthritis (RA). Patients with RA are at an increased risk of infections, which may be attributed to either the pathological mechanisms of RA itself or treatment‐related immunosuppression. Due to the rapidly evolving research and development of biologics, more therapeutic options for patients with RA are available than ever before. The particular immune targets, such as cell surface molecules, receptors and intracellular signalling pathways, lead to a diversity of infections. In this context, infections associated with each biologic and targeted drug are summarized to inform the stratification of patients, including the characteristics of the susceptible patients and these patients' concomitant therapies. We aim to provide a benefit‐risk analysis for clinical decisions, and vital indications for the prevention of highly correlated infections when RA patients are treated with biologic and targeted therapies.